ReviewInternational journal of molecular sciences2026
Epigenetic Modulation by Luteolin, Quercetin and Apigenin in Systemic Lupus Erythematosus and Rheumatoid Arthritis: Mechanisms and Therapeutic Perspectives.
Review in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
For many years, plants have long served as sources of potential therapeutic agents. Recently, there has been a growing interest in investigating the effects of plant bio-active compounds on epigenetic modulation of several processes-among them, modifications of DNA, histones, and microRNAs that influence gene expression. Aberrant epigenetic changes can affect key cellular processes by altering the expression of many important genes, leading to disturbances in human cells, and consequently, to various diseases including systemic autoimmune diseases. However, these modifications are reversible, offering a unique way for therapeutic intervention. Many plant-derived compounds possess the potential to modify these abnormal epigenetic modifications. Among these are apigenin, quercetin and luteolin, which can alter the level of histone acetylation, DNA methylation and miRs in cells. This review highlights these abnormal epigenetic alterations in two important autoimmune diseases in humans, i.e., lupus erythematosus and rheumatoid arthritis, and discusses the promising efficacy of these bio-active compounds in mitigating these deleterious epigenetic signatures. Furthermore, this review addresses ongoing clinical investigations to evaluate the therapeutic potential of these plant-derived compounds in the treatment of both systemic lupus erythematosus and rheumatoid arthritis, along with their limitations and challenges.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.